Daily PubMed evidence board
From Preservation to Regeneration: Stem Cell-Derived Therapies in Machine-Perfused Kidney Transplants - A systematic Review and Meta-analysis.
This systematic review and meta-analysis looked at studies that added stem cells or extracellular vesicles (small particles released by cells) to kidneys…
Signal score64Research triage score
CertaintyLow-to-ModerateVerify in full text
PMID42247338Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This systematic review and meta-analysis looked at studies that added stem cells or extracellular vesicles (small particles released by cells) to kidneys while they were being preserved on machine perfusion, with the goal of reducing injury from lack of blood flow and improving transplant outcomes. The authors found some reports of lower inflammation and lower injury biomarkers in individual experiments, but when results were pooled there were no clear improvements in measures such as creatinine clearance, urine output, or the biomarker NGAL. Histology and cell retention findings were inconsistent, and only one study looked at real post-transplant function. Overall, the review concludes that while there are promising biological signals, consistent functional benefits have not been demonstrated and more standardized, transplant-model studies with longer follow-up are needed.
Why it matters
- Addresses ischemia-reperfusion injury mitigation in kidney transplantation, a key determinant of early graft function and transplant outcomes.
- Evaluates cell-based (stem cells) and extracellular vesicle (EV) therapies delivered during machine perfusion - an emerging intraoperative/organ-preservation intervention with potential to change preservation protocols.
- Reports on clinically relevant intermediate outcomes (renal function, biomarkers, inflammation, histology) that inform decisions about moving to transplant models and clinical trials.
Primary outcomes
- Renal function (creatinine clearance, urine output)
- Injury biomarkers (e.g., NGAL)
- Inflammation (e.g., IL-6, IL-1β)
- Histology
Effect summary
Based on abstract-pooled results: no significant pooled effect on creatinine clearance (SMD 0.00; 95% CI -0.54 to 0.55), urine output (SMD 0.54; 95% CI -0.46 to 1.55), or NGAL (SMD -1.68; 95% CI -5.60 to 2.25). Some individual studies reported reductions in inflammatory cytokines and biomarkers, but functional benefits were inconsistent and only one study assessed post-transplant outcomes.
Benefit-cost lens
| Quick take | Meta-analysis found no consistent functional benefit of stem cell/EV delivery during machine perfusion despite some reductions in inflammatory markers in individual studies; claims of healthcare benefit require full-text effect sizes, costs, target-population estimates, and implementation assumptions. |
|---|---|
| BCR anchor | 2 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Assessment based on PubMed metadata and abstract only; full text may change effect estimates, heterogeneity interpretation, and applicability. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | rapid-abstract-screen |
|---|---|
| Verdict | Some concerns |
| Notes | Assessment based solely on PubMed metadata and abstract. The review pools heterogeneous experimental models and protocols (animal and discarded human kidneys) and few studies assessed transplant outcomes; study-level risk of bias, publication bias, and GRADE were not extractable from abstract. |
Harms, equity, conflicts & implementation
| Implementation | Full-text review to extract standardized effect sizes and protocols; GMP-grade cell/EV production capacity; perfusion-device compatibility testing; regulatory and ethical approvals; cost and workflow analyses; and pilot clinical/transplant-model studies with predefined safety and efficacy endpoints. |
|---|---|
| Equity impact | Unclear from abstract. Equity implications depend on access to advanced perfusion infrastructure and cell/EV manufacturing capacity; these may widen disparities unless implemented with equitable resource planning. |
| Harms | No harms or adverse-event data reported in abstract. Potential risks (immunologic reactions, prothrombotic effects, contamination, or off-target effects) require verification in full text and primary studies. |
| Replication | Unknown from abstract-only screening; replication across standardized transplant models not demonstrated in abstract. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.